- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin.1,2 The speaker(s) will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia. Objectives:
- Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
- Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
- Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology
References
- Dedic N, et al. Int J Mol Sci. 2021;22(24):13185. doi:10.3390/ijms222413185
- Nair PC, et al. Mol Psychiatry. August 10, 2021. doi:10.1038/s41380-021-01250-7
Featuring
Christoph Correll, MD
Chair of the Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy, Charité Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany. Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA.
MoreProfessor Correll’s research and clinical work focus on the identification, characterization and treatment of youth with severe mental illness, including psychotic and mood disorders, spanning all disease stages from the prodrome to first and multi-episode illness and up to refractory illness. He further focuses on psychopharmacology, epidemiology, comparative effectiveness, meta-analyses, the risk–benefit evaluation of psychotropic medications, and the interface between physical health and mental health.Jehan Marino, PharmD, BCPP (OPDC)
Medical Science Liaison
Speaker Christoph Correll, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Jehan Marino, PharmD, BCPP is an employee for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Related Events
-
Addressing Caregiver Burden & Identifying Agitation in Alzheimer’s Dementia
November 13 12:00 pm to 1:00 pm -
Post-Traumatic Stress Disorder (PTSD): Clinical Considerations & Unmet Needs
November 15 12:00 pm to 1:00 pm
Registration
Related Resources
-
Introduction to PTSD
Infographic November 11, 2024This infographic aims to raise awareness of PTSD in a straightforward manner appropriate for both individuals with lived experience, and health care providers.
-
Factors in Designing & Evaluating Clinical Trials for App-Based Interventions
On-Demand Webinar November 4, 2024In this webinar, Dr. Sara Morimoto, PsyD will share her expertise in developing and testing app-based mental health interventions.
-
Talking Points (Part III): Primary Care on Agitation – David Lewis
Podcast November 4, 2024Listen to Amica Simmons-Yon, PharmD, PhD as she spills the tea on a new Talking Points Series from Primary Care on Agitation associated with Alzheimer’s Dementia (AAD). In Part III…
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: